1316761-71-3

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 37687-24-4 diethyl 1H-pyrazole-3,5-dicarboxylate 
• 2393-23-9 4-methoxy-benzylamine 
• 1316761-72-4 diethyl 1-(2-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate 
• 1316761-74-6 1-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-2-bromoethan-1-one 
• 1272403-00-5 5-bromo-N,N-bis[(4-methoxyphenyl)methyl]pyrimidin-2-amine 
• 854391-95-0 bis(4-methoxybenzyl)amine hydrochloride 

Downstream Products

• 1316761-69-9 C₂₉H₂₇ClN₆O₄ 
• 1316761-67-7 C₃₃H₃₅N₇O₅ 
• 1316761-65-5 C₃₁H₃₃N₇O₄ 
• 1316761-63-3 C₃₁H₃₁N₇O₄ 
• 1316761-62-2 C₃₆H₄₃N₉O₅S 
• 1349901-64-9 C₃₄H₃₈N₈O₅ 
• 1349901-67-2 C₃₁H₃₂N₈O₄ 
• 1349901-68-3 C₃₂H₃₄N₈O₄ 
• 1349901-69-4 pyrrolidin amide 
• 1349901-70-7 C₃₆H₄₁N₉O₄ 
• 1349901-71-8 C₃₆H₄₃N₉O₄ 

Relevant academic research and scientific papers

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Identification of novel PI3K inhibitors through a scaffold hopping strategy

A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery of novel PI3K inhibitors. Compounds were designed based on the chemical structure of the lead compound ETP-46321, a potent PI3

NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS

There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS

There is provided compounds of formula (I), wherein A1, A4, A4a,A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

INHIBITORS OF PI3 KINASE

There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.